Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer
This is a multicenter, open-label, single-arm, prospective, phase II study. conducted to evaluate the efficacy, safety and tolerability of nab-paclitaxel plus pyrotinib in patients with lymph node-negative and tumor size ≤3 cm, HER2 positive breast cancer.
Early Breast Cancer
DRUG: Nab-paclitaxel in combination with pyrotinib
3-year-DFS, 3-years-disease free survival rate, From the start of treatment to 3 years
AEs+SAEs, Adverse Events and Serious Adverse Events are described in terms of CTC AE 5.0, from the first drug administration to within 28 days for the last pyrotinib dose
This is a multicenter, open-label, single-arm, prospective, phase II study. conducted to evaluate the efficacy, safety and tolerability of nab-paclitaxel plus pyrotinib in patients with lymph node-negative and tumor size ≤3 cm, HER2 positive breast cancer.